01 — At a Glance
The 14th-Largest Indian Pharma Company That’s Secretly Building Something Global
Glenmark Pharmaceuticals is one of those weird Indian pharma companies that nobody mentions at dinner parties but everyone in the industry respects. It’s the 14th largest player in India (IQVIA rank). The 15th biggest by generic prescriptions filled in the USA. Fifth in Europe. Operating across 80 countries. And for the past 5 years, it’s been quietly building a specialty and oncology portfolio while simultaneously generating hard cash from generics.
Q3 FY26 (December quarter): Consolidated revenue at ₹39,006 million, up 15.1% YoY. Quarterly profit at ₹403 crore, up 55.2% YoY. EPS at ₹14.29 (annualized: ₹57.16). And here’s the kicker — in September 2025, AbbVie just wrote them a $700 million upfront cheque for exclusive global rights to their cancer asset ISB 2001. Not a partnership. Not a loan. Cash. For a molecule in Phase I. This is not normal behaviour for cautious Indian pharma.
- 52-Week High / Low₹2,286 / ₹1,336
- Q3 FY26 Revenue₹39,006 Mn
- Q3 FY26 PAT₹403 Cr
- Quarterly EPS₹14.29
- Annualised EPS (Q3×4)₹57.16
- Book Value₹340
- Price to Book6.26x
- Dividend Yield0.12%
- Debt / Equity0.13x
- Net Cash Position₹600 Cr (approx)
The Vibe Check: Q3 delivered on management’s “near-term guidance.” Consolidated sales up 15.1% YoY. Profit up 55.2%. India outperformed market growth by 4.8 percentage points. New respiratory approvals are incoming. Monroe facility (North Carolina) restarted operations post-FDA inspection with zero 483s. And then there’s that $700 million from AbbVie that’s sitting on the balance sheet making everyone nervous and excited at the same time.
02 — Introduction
The Global Generic Pill Factory That Fell In Love With Cancer Drugs
Glenmark Pharmaceuticals started like every other Indian pharma company — making copies of American drugs cheaper, shipping them abroad, making boring but reliable money. Revenue: predictable. Growth: steady. Returns: adequate. Problem: not sexy enough for a 35% stock CAGR over 5 years.
So around 2018-2020, they pivoted. They bought Ichnos Sciences, a US-based biotech innovation engine focused on oncology and autoimmune diseases. They started filing patents like they owed someone money. They inked licensing deals with AbbVie, Hengrui, Almirall, Cosmo. And suddenly, a generics company became a specialty pharma story with oncology tailwinds and cash flow that doesn’t rely on selling you a copy of Aspirin at 10% cheaper than the original.
The result? Stock up 51% in 1 year. Up 71% in 3 years. Up 34.9% in 5 years. Not Reliance-level returns, but for a company selling pills, that’s genuinely impressive. And Q3 FY26 just proved this wasn’t luck — it was strategy coming online.
This article breaks down the numbers, the narrative, and the weird reality: Glenmark is no longer a generic pharmaceutical company. It’s a global specialty pharma company that still sells generics to keep the lights on.
💬 Do you think Indian pharma can compete on specialty drugs? Or is generics their eternal destiny? Drop your take in the comments.
03 — Business Model: Pills, Patents & Probabilities
Three Revenue Streams, One Overarching Strategy
The Generics Grind: Glenmark makes unbranded copies of existing drugs (after patents expire). India generics. North America (USA/Canada). Europe. Emerging markets. This segment is 70-75% of revenue — steady, competitive, mature. Profit margins: 18-22%. Growth rate: 4-6% annually. Competitive advantage: scale, cost structure, regulatory approvals. Weakness: commoditizing. Anyone with an USFDA factory can do this.
Specialty & Branded: Here’s where Glenmark acts like it’s Swiss or German. They own branded respiratory products (RYALTRIS for allergic rhinitis, respiratory launches in India). Dermatology (WINLEVI for acne, JABRYUS for atopic dermatitis). Metabolic (Lirafit biosimilar for diabetes). Growing 20%+ annually. Margins: 40-50%+. This is the future play.
Innovation/Licensing: Via subsidiary Ichnos Sciences, Glenmark is now licensing out cancer and autoimmune molecules to global pharma majors. ISB 2001 (oncology, Phase I) was just licensed to AbbVie for $700 million upfront + potential milestones. Trastuzumab Rezetecan licensed from Hengrui for ~$18 million upfront. Aumolertinib (EGFR inhibitor) licensed globally. These deals generate milestone payments AND margin accretion as the company commercializes in licensed territories.
The geographic split (9M FY26): India 25% | North America 24% | Europe 18% | Rest of World 21% | API 12%. Translation: they’re not betting the house on any single market. Diversification is baked in.
Concall Insight (Feb 2026): Management explicitly stated: “If we get these new product approvals in Q4, you will see a definite uptick in the gross margin.” Respiratory is the swing factor. Flovent generic approval is imminent. When it lands, margin expansion accelerates.
04 — Financials Overview
Q3 FY26: The Numbers Game
Result Type: Quarterly Results (Q3 Dec 2025) | Q3 EPS: ₹14.29 | Annualised EPS (Q3×4): ₹57.16 | Recalculated P/E: 37.1x (vs stated 22.2x which uses FY25 full-year EPS of ₹37.7)
| Metric (₹ Mn) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 39,006 | 33,876 | 36,234 | +15.1% | +7.6% |
| Operating Profit | 8,700 | 7,850 | 9,060 | +10.8% | -3.9% |
| OPM % | 22.3% | 23.2% | 25.0% | -90 bps | -270 bps |
| PAT | 403 | 260 | 373 | +55.2% | +8.0% |
| EPS (₹) | 14.29 | 9.24 | 13.26 | +54.7% | +7.7% |
The Margin Plot Twist: Revenue up 15.1%, profit up 55.2%. That’s not linear math — that’s mix improvement + operating leverage. OPM compressed from 23.2% to 22.3% YoY, but that’s because of one-time items (US settlements: $37.75 million in Q3). Strip those out, core OPM is actually stable. The PAT jump is 55.2% because of “currency depreciation across key geographies” (per management). FX was a tailwind. When it reverses, margins will normalise.
💬 When the FX tailwind reverses (and it will), can Glenmark defend 55%+ profit growth through volume and specialty mix? Or was Q3 a one-time party?
05 — Valuation: Fair Value Range
What’s a Pharma Company Worth When It’s Morphing Into Something Else?
Join 10,000+ investors who read this every week.
